Zydus Cadila is the first company to launch a biosimilar of Amgen’s Adalimumab, a top selling therapy for rheumatoid arthritis and other autoimmune disorders. The biosimilar has been approved by the Drug Controller General of India and will be marketed under the brand name Exemptia, to treat autoimmune disorders such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and Ankylosing Spondylitis.   The new process and formulation of Adalimumab have been researched, develo...